Neldaleucel · MT-601

What is Neldaleucel?

Neldaleucel (MT-601) is an autologous cell therapy comprising ex vivo-expanded CD4+ and CD8+ T cells expanded to recognize six tumor-associated antigens. The T cells bind to and kill cancer cells expressing these antigens. It is being studied in relapsed/refractory non-Hodgkin and Hodgkin lymphomas and pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

MT-601

Drug type

Cell therapy (Antigen-specific T cells)

Targets

neoantigens (antigen)

Mechanism

Kills target cells, directed at neoantigens

Therapy area

Oncology

Developer

Marker Therapeutics, Inc. (MRKR)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1

UNII

78SU4N7MVG

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hodgkin LymphomaHodgkin Lymphoma, AdultHodgkin's Lymphoma, Relapsed, AdultNon Hodgkin LymphomaNon-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, RelapsedPancreas CancerPancreatic Cancer (Unresectable)Pancreatic Cancer Metastatic

More from Marker Therapeutics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05798897
• ClinicalTrials.gov NCT06549751
• ClinicalTrials.gov NCT06549751
• ClinicalTrials.gov NCT06549751

Updated Oct 3, 2026.